The administration of this molecule reduced the level of G-CSF (CSF3) produced by tumor cells, with (as a consequence an impaired recruitment of MDSCs) increased immunogenic cell death and the promotion of an inflammatory environment with increase in M1-like TAMs potentially arising from the differentiation of MDSCs [33]. This evidence concerns the gene CSF3 and neoplasm.